Analysis

Eli Lilly reported that pirtobrutinib (Jaypirca) met the primary endpoint in the Phase 3 BRUIN CLL-313 trial, demonstrating an 80% reduction in the risk of disease progression or death versus bendamustine plus rituximab (BR) in 282 treatment‑naïve CLL/SLL patients without del(17p) at a median follow‑up of 28.1 months. The study was randomized 1:1 with crossover allowed after IRC‑confirmed progression and is the first prospective Phase 3 trial of a non‑covalent BTK inhibitor in the front‑line setting. Progression‑free survival favored pirtobrutinib across all pre‑specified subgroups, and overall survival data remain immature but trend in pirtobrutinib’s favor despite more than half of BR patients crossing over to pirtobrutinib, a factor likely to attenuate observable OS separation prior to final testing. Lilly has begun submitting BRUIN CLL‑313 and BRUIN CLL‑314 data to regulators to pursue label expansion into earlier lines of therapy, and the company is running multiple Phase 3 studies to support that effort. Market signals are strongly positive (sentiment score 0.8, market impact 0.7), reflecting the potential commercial and competitive significance if regulators accept the data, but key uncertainties remain around final OS confirmation, regulatory review outcomes, and longer‑term safety and uptake in the front‑line treatment paradigm.